Adaptimmune Therapeutics (STU:473A) Gross-Profit-to-Asset % : 4.73% (As of Dec. 2024)

Adaptimmune Therapeutics Gross-Profit-to-Asset % Chart

Adaptimmune Therapeutics Annual Data
	Trend	Jun15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Gross-Profit-to-Asset %		Get a 7-Day Free Trial					1.22	1.38	7.06	19.41	68.80

Adaptimmune Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															0.32	8.42	177.73	50.41	4.73

Competitive Comparison of Adaptimmune Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Adaptimmune Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's Gross-Profit-to-Asset % falls into.

Adaptimmune Therapeutics Gross-Profit-to-Asset % Calculation

Adaptimmune Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Adaptimmune Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Adaptimmune Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics Business Description